Cargando…

The Prognostic Value of Time in Range in Type 2 Diabetes

Detalles Bibliográficos
Autor principal:	Selvin, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2021
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818332/ https://www.ncbi.nlm.nih.gov/pubmed/33472967 http://dx.doi.org/10.2337/dci20-0066

Ejemplares similares

Continuous glucose monitoring targets in type 1 diabetes pregnancy: every 5% time in range matters
por: Murphy, Helen R.
Publicado: (2019)

The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes
por: Strain, W. David, et al.
Publicado: (2021)

One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2021)

Clinical Inertia in Individualising Care for Diabetes: Is There Time to do More in Type 2 Diabetes?
por: Strain, William David, et al.
Publicado: (2014)

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
por: Schernthaner, Guntram, et al.
Publicado: (2018)

Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation?
por: Marinoni, Ilaria
Publicado: (2022)

Connecting the Dots: Validation of Time in Range Metrics With Microvascular Outcomes
por: Hirsch, Irl B., et al.
Publicado: (2019)

Hints of Unique Genetic Effects for Type 2 Diabetes in India
por: Holliday, Elizabeth G.
Publicado: (2013)

Glycosylated haemoglobin (A1c) best values for type 2 diabetes in the battlefield much ado about nothing? (apparently)
por: Maggi, Davide, et al.
Publicado: (2019)

Prognostic value of biomarkers in primary small cell carcinoma of the esophagus
por: Wang, Yan, et al.
Publicado: (2020)

Time above range for predicting the development of type 2 diabetes
por: Marco, Alejandra, et al.
Publicado: (2022)

Assessing liver fibrosis in all patients with type 2 diabetes and fatty liver disease: It's time to act now
por: Lee, Chi Ho, et al.
Publicado: (2022)

Insulin Resistance and Type 2 Diabetes
por: Taylor, Roy
Publicado: (2012)

Increased Time in Range with Ultra Rapid Lispro Treatment in Participants with Type 2 Diabetes: PRONTO-Time in Range
por: Bailey, Timothy S., et al.
Publicado: (2023)

Commentary: The Prognostic Value of Oligo-Recurrence Following Esophagectomy for Esophageal Cancer
por: Mine, Shinji
Publicado: (2023)

Comment on Bonnet et al. Association Between Handedness and Type 2 Diabetes: The E3N Study. Diabetes Care 2015;38:e199
por: Selvin, Elizabeth
Publicado: (2016)

Thirty-Year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes
por: Fang, Michael, et al.
Publicado: (2021)

Tipping Points – Do the Prognostic Values of Multimorbidity and Functional Status Vary with Age?
por: Thygesen, Lau Caspar, et al.
Publicado: (2021)

Prognostic value of pulmonary dead space in patients with the acute respiratory distress syndrome
por: Matthay, Michael A, et al.
Publicado: (2011)

The residual cardiorenal risk in type 2 diabetes
por: Giugliano, Dario, et al.
Publicado: (2021)

Exercise in type 2 diabetes: to resist or to endure?
por: Roden, M.
Publicado: (2012)

Pharmacoepigenetics in type 2 diabetes: is it clinically relevant?
por: Ling, Charlotte
Publicado: (2022)

Commentary: Educational intervention in type 2 diabetes
por: Singh, Raminder
Publicado: (2023)

Burden of Complications in U.S. Adults With Young-Onset Type 2 or Type 1 Diabetes
por: Fang, Michael, et al.
Publicado: (2020)

Time-in-range as a target in type 2 diabetes: An urgent need
por: Saboo, Banshi, et al.
Publicado: (2021)

Diabetic ketoacidosis at presentation of type 1 diabetes in children in Canada during the COVID-19 pandemic
por: Sellers, Elizabeth A C, et al.
Publicado: (2021)

Effect of real‐time continuous glucose monitoring on hypoglycemia in adult type 1 diabetes patients
por: Jia, Weiping
Publicado: (2017)

Phenotypic heterogeneity in circulating tumor cells and its prognostic value in metastasis and overall survival
por: Saxena, Kritika, et al.
Publicado: (2019)

Prognostic value of epigenomic profiling in lung cancer
por: Mishra, Alok, et al.
Publicado: (2019)

Variation of glucose time in range in type 1 diabetes
por: Hansen, Klavs Würgler, et al.
Publicado: (2022)

Values and Limitations of Targeting lncRNAs in Diabetic Nephropathy
por: Long, Jianyin, et al.
Publicado: (2018)

Public Health Genomics Approach to Type 2 Diabetes
por: Khoury, Muin J., et al.
Publicado: (2008)

Primary Prevention of Type 2 Diabetes: There Are No Simple Solutions!
por: Cefalu, William T.
Publicado: (2009)

Anti-atherogenic effects of fibrates in type 2 diabetes
por: Barter, Philip
Publicado: (2001)

Clinical challenges: Myeloma and concomitant type 2 diabetes
por: Ali, Mohamed Ahmed, et al.
Publicado: (2013)

Management of hyperglycemia in type 2 diabetes: evidence and uncertainty
por: Esposito, Katherine, et al.
Publicado: (2013)

A proteomic approach to obesity and type 2 diabetes
por: López-Villar, Elena, et al.
Publicado: (2015)

β‐Cell senescence in the pathogenesis of type 2 diabetes
por: Imai, Junta
Publicado: (2019)

The Benefits and Risks of New Therapies for Type 2 Diabetes
por: Asche, Car V., et al.
Publicado: (2008)

Commentary on glucose reduction in type 2 diabetes (GRADE)
por: Lee, Yi‐Hong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_93ml5ajlbsmcaj5q2ftld7b6dg